BN 82451

Drug Profile

BN 82451

Alternative Names: BN-82451B; BN82451

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ipsen
  • Class Amines; Neuroprotectants; Phenols; Small molecules; Thiazoles
  • Mechanism of Action Lipid peroxidation inhibitors; Monoamine oxidase B inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Discontinued Amyotrophic lateral sclerosis; Parkinson's disease

Most Recent Events

  • 31 May 2016 Ipsen completes enrolment in its phase II trial for Huntington's disease in Germany (NCT02231580)
  • 01 Sep 2014 Phase-II clinical trials in Huntington's disease in Germany (PO)
  • 26 Nov 2013 Phase-II clinical trials in Huntington's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top